Development of anticancer drug targeting choline transporter by drug repositioning
| Project/Area Number |
17K08315
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pharmacology in pharmacy
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
Inazu Masato 東京医科大学, 医学部, 教授 (00297269)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | コリン / トランスポーター / がん治療 / choline / transporter / cancer / ceramide / survivin / apoptosis / 癌 / ドラッグリポジショニング / 薬理学 |
|---|
| Outline of Final Research Achievements |
A novel choline transporter-like protein 1 (CTL1) was found to be highly expressed in cancer cells, and its inhibition induced apoptosis and suppressed cell growth. Furthermore, the search for CTL1 inhibitors from existing pharmaceutical and plant-derived organic compound libraries led to the discovery of promising isoquinoline derivatives. This hit compound may be a candidate for a new molecularly targeted cancer drug with a novel therapeutic mechanism.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は、これまでの抗がん剤が標的としていない新規のがん治療標的分子であるcholine transporter-like protein 1 (CTL1)を見出し、このCTL1を阻害しアポトーシスによる細胞死を誘導する化合物を発見した。本ヒット化合物のメカニズムも明らかにし、癌細胞移植ヌードマウスにて抗腫瘍効果を確認した。本研究における成果は、新たな分子標的治療薬の開発に繋がり、予防・治療医学および創薬科学への発展に貢献するものである。
|
Report
(4 results)
Research Products
(25 results)
